References World Health Organization. American Cancer Society. Cancer Facts & Figures 2010th Atlanta: American Cancer Society, American Lung Association. Understand cancer.Source: Regeneron Pharmaceuticals.
NovaLign Orthopaedics,progression-free survivalneron Report Top-line Results from Phase III Study with aflibercept in Second-Line Non – Small Cell Lung CancerSanofi-aventis and Regeneron Pharmaceuticals are the results from the phase III VITAL trial evaluating the investigational agent aflibercept in the second-line treatment of non – small cell lung cancer . The data showed that the addition of aflibercept to the chemotherapy drug docetaxel did not show the specified criteria for the primary endpoint of improvement overall survival compared to treatment with docetaxel plus placebo compared and an overall objective response rate of 23.3 percent in the aflibercept arm to 8.9 % in the placebo arm.Use of fennel extract, tea and sugar solution was the majority effective. In relieving colic babies Other treatment assessed contain probiotic supplements, massage and reflex but the outcomes were inconclusive. The authors determined, – of colic, and CAM therapies they examined do not significantly reduce the symptoms of colic, and additional research being requires in finding of a successful treatment..